Uncategorized
« Previous EntriesCell Therapeutics Dilutes Shareholder Value (CTIC)
Submitted by BioHealth Investor Blog
by Zacks Investment Research
Cell Therapeutics, Inc. (NASDAQ: CTIC) recently decided to exchange up to 60 million shares of its common stock for $30 million of notes. Liquidity crisis at the company continues to remain a major concern for us. Earlier, in April 2010, the company raised $18.5 million through preferred stock [...]
Amgen and the War on Bone Tumors (AMGN)
Submitted by BioHealth Investor Blog
Amgen Inc. (NASDAQ: AMGN) has submitted a BLA, a Biologics License Application, to the U.S. FDA for denosumab. The BLA submission summarizes trial data as a “clinical experience from nearly 6,900 patients across 18 clinical studies” including approximately 5,700 patients with advanced cancer in the three, pivotal, Phase 3, head-to-head trials [...]
Ikaria: BioHealth IPO with Profits and Revenues
Submitted by BioHealth Investor Blog
The newest initial public offering in the realm of biotech and biohealth has just been filed by a company called Ikaria Inc. While terms were not disclosed, it plans to sell up to $200 million in common stock per the SEC filing.
The New Jersey-based biotherapeutics company plans to take the ticker [...]
NicOx: When Hell Breaks Loose in Foreign Stocks
Submitted by BioHealth Investor Blog
NicOx S.A. (NYSE Euronext Paris: COX) is not a US company and only has a Pink Sheet listing. Generally we do not cover such issues, but this is one of the instances where it is merited.
Today the company’s shares were dealt a serious blow after the company confirmed that the Joint [...]
Sequenom Secures Turnaround Capital (SQNM)
Submitted by BioHealth Investor Blog
Sequenom, Inc. (NASDAQ: SQNM) must really have its woes of 2009 behind it. If not, raising capital might be impossible. This morning came news that it has raised over $50 million in a private placement of securities. The problem is that this is at one hell of a discount.
The company has [...]
New reference pricing rule in Greece
Submitted by THE HEALTH ECONOMICS BLOG
After much debate the Greek Ministry of Economy, Competitiveness & Shipping has announced a new reference pricing law for pharmaceuticals. The struggling Greek economy is looking for opportunities to realize savings in the health care sector and has introduced a decree of mandatory price reductions. Depending on wholesale price reduction [...]
Option Trader Take: Caution In MannKind (MNKD, BIOD)
Submitted by BioHealth Investor Blog
We were just given a cautious options alert from Joe Kunkle of OptionsHawk.com on shares of MannKind Corp. (NASDAQ: MNKD). After the unexpected meteoric rise earlier this year and then last night’s and this morning’s unexpected implosion of InterMune, it seems that traders and investors are taking a much more cautious [...]
Dendreon Snapshot Pre-Decision (DNDN)
Submitted by BioHealth Investor Blog
Dendreon Corporation (NASDAQ: DNDN) continues to see traders and investors position and reposition ahead of the FDA decision on PROVENGE for advanced prostate cancer. A $40 MAY-2010 STRADDLE currently costs right at $13.00, so volatility buyers are effectively betting that Dendreon would drop to under $27 or rise to above $53 [...]
Generex, Progress on Trials and Progress on Financing (GNBT)
Submitted by BioHealth Investor Blog
Generex Biotechnology Corporation (NASDAQ: GNBT) had already reported that it had found a financial backer earlier this month when it announced that it would sell up to 49.5 million shares, and it has an existing and effective shelf registration statement already. The company has entered into a common stock purchase agreement [...]
FDA Battening Conflict of Interest Hatches, Maybe
Submitted by BioHealth Investor Blog
The United States Food and Drug Administration is going to get tougher on disclosure of conflicts of interest. At least that is the aim. The FDA has announced new draft guidance, which is of course subject to change and alteration, that seeks to expand transparency and disclosure when the agency grants [...]
Array and Novartis Choose Pact Over Merger (ARRY, AZN)
Submitted by BioHealth Investor Blog
Array BioPharma Inc. (NASDAQ: ARRY) is not usually the most active stock during the regular trading sessions of any day, let alone for it to be one of the most active in the after-hours trading session. Yet this evening Array is very active, and active to the upside. If you read [...]
Ten-Bagger Chase Goes After Prana (PRAN)
Submitted by BioHealth Investor Blog
Prana Biotechnology Ltd. (NASDAQ: PRAN) is up over 100% today on some published data. The share trading activity is indicative of traders and investors looking for the next biotech ten-bagger, or that search for a 1,000% Gainer.
The report causing the run-up is new published analysis of its clinical trial excerpt taken [...]
Very Few 52-Week Highs in BioHealth (ACOR, ALTH, ARIA, AUXL, KERX, NPSP, PPDI, PPHM, PBE, PRX, SUPG)
Submitted by BioHealth Investor Blog
The market has been putting new highs and new highs and yesterday there were about 1700 stocks (including warrants, ETFs, and other publicly traded non-common entities). What is interesting is that biotech and pharma stocks are few and far between that are actually putting in new 52-week highs. Many of the [...]
Chase for Ten-Baggers Keeps After Cancer (MIPI, ENMD)
Submitted by BioHealth Investor Blog
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI) is surging this morning on solid news in the war on cancer. Any time you have a gain of 100% or more in a single day, the term “surge” is an understatement. The move is on the heels of results from a completed Phase II [...]
Cell Therapeutics… The Pixantrone Fight Continues (CTIC)
Submitted by BioHealth Investor Blog
Cell Therapeutics, Inc. (NASDAQ: CTIC) is in the news again, and not just over its special meeting of shareholders. In the middle of the night, Cell Therapeutics announced that the company has received a Complete Response Letter from the FDA over its new drug application for Pixuvri (pixantrone dimaleate) for relapsed [...]
Bets on OSI-Astellas Stand-Off (OSIP)
Submitted by BioHealth Investor Blog
OSI Pharmaceuticals Inc. (NASDAQ: OSIP) looks innocent enough today. Shares are barely up in positive territory at $60.00 today and share trading volume is light. Yet there may be a bet brewing that OSI might not be able to milk much more either out of Astellas nor from a rival offer. [...]
Debating Dendreon’s Future Versus Reality (DNDN)
Submitted by BioHealth Investor Blog
Dendreon Corp. (NASDAQ: DNDN) broke over $40.00 today. This does not just mark a 52-week high. It is an all-time high. The run-up is ahead of the FDA decision on Provenge as a last line of defense in prostate cancer patients being less than a month out. We are watching the [...]
Cell Therapeutics Bracing For Shareholder Event (CTIC)
Submitted by BioHealth Investor Blog
Cell Therapeutics Inc. (NASDAQ: CTIC) is still in trouble after its recent implosion. But traders have still been swinging this stock around each day on one report or another, and we are finally starting to see a break or compression in the intra-day volatility in this biotech stock.
Last week the company [...]
When Biotech Analysts See Exponential Price Gains (OXGN, INO, NVAX, OREX, SQNM, VNDA)
Submitted by BioHealth Investor Blog
If you have been a reader of BioHealth Investor for very long, you know what the quest for ten-baggers happens to be. The chase for 1,000% gains is hard to find outside of biotech stocks. In fact, looking for ten-baggers is a very risky business venture because it is no different [...]
ArQule’s Ten-Bagger Chase, Actually a 3-Bagger (ARQL)
Submitted by BioHealth Investor Blog
ArQule, Inc. (NASDAQ: ARQL) may not quite be representative of the quest for ten-baggers, but this is something that should be watched by biotech traders and investors. When you see biotech and BioHealth stocks up 100% in a day you just have to assume that it will be on the trading [...]
10-Bagger Quest Chases ARCA biopharma (ABIO)
Submitted by BioHealth Investor Blog
ARCA biopharma, Inc. (NASDAQ: ABIO) was not just the big winner of the trading day. It was an exponential gainer. You rarely see this unless there is a major biotech announcement regarding cancer or other other disease cures. But in the quest for ten-baggers in biohealth, ARCA Bio at least formed [...]
Will CEO Termeer Survive Genzyme’s Woes? (GENZ, PLX, SHPGY, PFE)
Submitted by BioHealth Investor Blog
Genzyme Corporation (NASDAQ: GENZ) has been one of the top biotech companies in history. Its drug pipeline and then its drug portfolio have helped lead it to exponential rewards for shareholders through time. But nothing lasts forever, and management often has to pay the price. The calls for the ouster of [...]
Major Short Selling Changes in Biotech (AMGN, BIIB, GILD, CELG, GENZ, GERN, DNDN, HGSI, AMLN, CTIC)
Submitted by BioHealth Investor Blog
We have now seen the changes in short selling in biotech stocks via the Mid-March short interest report from NASDAQ. This marks the changes seen at the March 15, 2010 settlement date versus a prior February 26 settlement date. We took a look at Amgen Inc. (NASDAQ: AMGN), Biogen Idec Inc. [...]
Loosening the CytRx and RXi Puppet Strings (CYTR, RXII)
Submitted by BioHealth Investor Blog
Investors have a love and hate relationship with tracking stocks. That also pertains to public companies which own large amounts of shares in other public companies. Every time we see a move in CytRx Corporation (NASDAQ: CYTR), we also see a move in conjunction with or in sympathy with RXi Pharmaceuticals [...]
Biosante Scores, Trial News and Orphan Drug Designation (BPAX)
Submitted by BioHealth Investor Blog
Biosante Pharmaceuticals, Inc. (NASDAQ: BPAX) is not your normal big mover, and it does not yet emulate what we would pen as the “chase for the next ten-bagger” where investors are looking for 1,000% gainers. But the company is seeing a surge in shares this morning after releasing additional positive Leukemia [...]
